Tuberculosis (TB), a chronic infectious disease caused by Mycobacterium tuberculosis, poses a significant threat to global health. With an estimated one-third of the world's population infected, and a substantial gap between estimated and diagnosed cases, the need for improved diagnostic strategies is urgent.
Current TB detection methods have limitations. Bacteriological examinations, while considered the gold standard, suffer from low sensitivity and long processing times. The tuberculin skin test (TST) is influenced by comorbidities and immune status, and its cross-reactivity with the BCG vaccine raises concerns. Early screening and diagnosis of pulmonary TB are crucial to control its spread, especially in high-burden countries like China, where TB incidence ranks third globally.
To address these challenges, researchers have identified lipoarabinomannan (LAM) as a promising diagnostic method. LAM, a key component of the Mycobacterium tuberculosis cell wall, is metabolized and excreted in urine, making it a potential biomarker for active TB and latent infection. Measuring LAM levels can improve TB diagnosis, predict clinical risks, and assess prognosis.
This study evaluates the accuracy of a new LAM detection kit produced by Guangzhou Reador Biotechnology Co., Ltd. The kit uses a chemiluminescent method to measure LAM levels in urine. By comparing it with other diagnostic methods, the research aims to explore the sensitivity of this assay and provide insights for clinical TB testing.
The study included 193 participants from the Fourth People's Hospital of Nanning, with a focus on suspected TB cases and patients requiring TB-related tests. Urine and sputum samples were collected, and a composite reference standard was used to define TB diagnosis. The chemiluminescence immunoassay method was employed to detect LAM content in urine.
Results showed that the LAM test kit performed well for qualitative detection of LAM levels in human urine samples, aiding TB diagnosis. LAM testing demonstrated high specificity and improved detection rates when combined with traditional pathogen detection methods. It also showed a high positive agreement rate in diagnosing TB, with a negative agreement rate of 94.29%, effectively reducing false positives.
Compared to traditional diagnostic methods like sputum smear, sputum culture, and molecular biology testing, LAM testing exhibited a significantly higher detection rate. Combining urinary LAM antigen testing with traditional pathogen diagnostics may offer a novel approach for diagnosing pulmonary TB. The study found that LAM had an overall agreement rate of 80.73%, suggesting its specificity in TB detection, especially for ruling out non-TB cases.
LAM testing offers a non-invasive alternative for patients who have difficulty producing sputum, such as children and critically ill individuals. The diagnostic value of LAM urine testing aligns with previous international studies, indicating its potential for population-wide screening in high-TB-burden cities in China. LAM testing provides quick, easy, and cost-effective diagnostic information, making it suitable for primary healthcare institutions and resource-limited areas.
While LAM testing shows promise for TB diagnosis, the study had limitations, including a small sample size and concentration on a single region. Future clinical trials with larger samples and broader study areas are needed to validate the findings. Additionally, the results of each detection method involved qualitative evaluation only, and specific test values or detailed comparative analyses were not recorded.
In conclusion, the LAM test kit developed by Guangzhou Reador Biotechnology Co., Ltd. can be used for in vitro qualitative detection of LAM in human urine samples, aiding TB diagnosis. Urinary LAM antigen testing holds great promise for application in high TB burden areas, providing a theoretical basis for promoting urinary LAM assay in healthcare institutions in China.
